A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540

Inclusion Criteria: * Male or non-lactating, non-pregnant female subjects who are 40 years or older at the time of initial dosing --Physical status within normal limits for age and consistent with observations at Screening * Able to understand and comply with study procedures required and able and willing to provide written informed consent prior to any study procedures being performed Exclusion Criteria: * History of hypersensitivity, allergy or intolerance to omeprazole or other proton-pump inhibitors (PPIs) * History of hypersensitivity, allergy or intolerance to aspirin or any NSAID and/or a history of NSAID-induced symptoms of asthma, rhinitis, and/or nasal polyps * History of hypersensitivity or intolerance to clopidogrel * History of hepatitis B or C, a positive test for hepatitis B surface antigen, hepatitis C antibody, a history of human immunodeficiency virus (HIV) infection or demonstration of HIV antibodies * History of malignancy, treated or untreated, within the past five years, with the exception of successfully treated basal cell or squamous cell carcinoma of -Evidence of uncontrolled, or unstable cardio- or cerebrovascular disorder, which in the Investigator's opinion, would endanger a subject if he/she were to participate in the study * Presence of an uncontrolled acute, or a chronic medical illness, e.g., GI disorder, diabetes, hypertension, thyroid disorder, bleeding disorder, infection, which in the Investigator's opinion would endanger a subject if he/she were to participate in the study or interfere with the objective of this study * Schizophrenia or bipolar disorder * GI disorder or surgery leading to impaired drug absorption * \< 70% platelet aggregation at Screening * Donation of blood or plasma within 4 weeks of the study * PPI use or any enzyme inducing/inhibiting agents within 4 weeks prior to dosing * Taking any antiplatelet drug within 2 weeks of the screening visit or during the study, or more than two 325 mg doses of aspirin or more than 2 doses of any other NSAIDs within 14 days prior to the screening visit